

C01



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE

Office of the Dean

MEMORANDUM

To: Charles Nemeroff, M.D., Ph.D, Chair of Psychiatry and Behavioral Sciences

From: Brenda J. Seiton, J.D., Assistant Dean for Administration *BJS*

Subject: Conflict of Interest Cases Reviewed by the Committee

Date: December 22, 2005

Thank you for forwarding your annual report regarding your research projects that had conflicts of interest. In reviewing this report, we noticed that you did not comment on several projects that had ended recently and might have publications that would fall under the management plans.

A. 2003-046-01

“Measurement of Cerebrospinal Fluid Substance P Concentrations in Depression and Anxiety”, sponsored by Merck
 IRB Protocol No.: 821-2002
 Project Start Date: July 2002 Project End Date: June 2004
 A Clinical Trial using Existing Clinical Specimens sponsored by Merck
According to our information, this research project has ended. Please forward to the Dean’s Office copies of any publication, presentation, or press release related to this research with the disclosure statement highlighted as required by the management plan.

B. 2003-047-01

“Open Label Treatment with Duloxetine Hydrochloride Once-Daily dosing for Evaluation of Stabilization Dose in Patients with Major Depression”, sponsored by Lilly
 IRB Protocol No.: 937-2002
 Clinical Trial sponsored by Lilly
 Project Start Date: December 2002 Project End Date: December 2004
According to our information, this research project has ended. Please forward to the Dean’s Office copies of any publication, presentation, or press release related to this research with the disclosure statement highlighted.



Emory University School of Medicine
 Woodruff Health Sciences Center Administration Building
 1440 Clifton Road, N.E.
 Atlanta, Georgia 30322-4510

Tel:
 Fax:

The Robert W. Woodruff Health Sciences Center
An equal opportunity, affirmative action university

C. 2003-049-01

"The Role of the Neurotensin System in the Antipsychotic Properties of Olanzapine", a non-clinical study sponsored by Lilly

Budget Start Date: 9/29/2000

Project Start Date: 4/18/1994 Project ended 9/28/2003

Please forward to the Dean's Office copies of any publication, presentation, or press release related to this research with the disclosure statement highlighted and a copy of the independent reviewer's report.

D. 2003-052-01

"RIS-USA-275 A Six Month, Double-Blind, Randomized, International, Multi-center Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects with Schizophrenia Disorder", sponsored by Janssen

Project Start Date: 4/16/2002 Project End Date: 12/31/2003

According to our information, this project has ended. Please forward to the Dean's Office copies of any publication, presentation, or press release related to this research with the disclosure statement highlighted and a copy of the independent reviewer's report.

G. 2003-053-01

"A Neurocognitive and Functional Imaging Study of the Comparative Effects of Risperdal and Zyprexa on Memory Deficits Associate with Schizophrenia", sponsored by Janssen Pharmaceutical

Project Start Date: 3/1/99 Project End Date: 12/1/2003

During the performance of this study, you were listed as a co-investigator and a conflict of interest did exist. Dr. [REDACTED] was to review the data that is required by the original plan. Please forward to the Dean's Office copies of any publication, presentation, or press release related to this research with the disclosure statement highlighted and a copy of the independent review of the data.